C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
12/2002
12/05/2002	US20020183496 Human thymosin beta15 gene, protein and uses thereof
12/05/2002	US20020183495 High affinity humanized anti-CEA monoclonal antibodies
12/05/2002	US20020183494 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/05/2002	US20020183493 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/05/2002	US20020183276 Administering alkaline phosphatase (TNAP) inhibitor to the tissue or patient effective to inhibit TNAP expression or activity for decreasing matrix mineralization in a tissue
12/05/2002	US20020183275 Obtaining a large cloned genomic fragment; using bacterial homologous recombination to genetically modify to create a large targeting vector for use in eukaryotic cells (LTVEC); introducing LTVEC into eukaryotic cells; quantitative assay
12/05/2002	US20020183270 For therapy of cancer and for diagnosing tumorigenicity and other diseases
12/05/2002	US20020183269 Novel compounds
12/05/2002	US20020183251 For use as vaccines, and other drugs for the diagnosis and therapy of prostate cancer
12/05/2002	US20020183250 For use in therapy of sleep disorders
12/05/2002	US20020183247 Lipoparticle comprising a protein and methods of making and using the same
12/05/2002	US20020182751 Sperm cell selection system
12/05/2002	US20020182729 Proliferation of neuronal cells; obtain stem cels, incubate with antagonist of pitutary adenylate cyclase activating polypeptide, moitor proliferation of neuronal cells
12/05/2002	US20020182726 Calcium-independent negative regulation by CD81 of receptor signalling
12/05/2002	US20020182725 New antigen presenting cells, a process for preparing the same and their use as cellular vaccines
12/05/2002	US20020182706 Purification of viral envelope proteins; obtain cell, transfect with genetically engineered virus, lyse cell, recover envelope proteins
12/05/2002	US20020182703 Human defensin polypeptide Def-X, genomic DNA and cDNA, composition containing them and applications to diagnosis and to therapeutic treatment
12/05/2002	US20020182691 Nucleotide sequences coding transport protein for use in nervous system disorders
12/05/2002	US20020182685 In vivo generation of antibodies against antigens secreted in a host by transfected MEL cells
12/05/2002	US20020182683 Vascular endothelial growth factor 2
12/05/2002	US20020182681 Peptide for use in treatment of cancer, parkinson's and metabolic disorders
12/05/2002	US20020182676 Ob receptor and methods for the diagnosis and treatment of body weight disorders, including obesity and cachexia
12/05/2002	US20020182671 Polypeptide for use in the treatment, diagnosis, and prevention of cell proliferative, autoimmune/inflammatory, neurological and gatrointestinal disorders
12/05/2002	US20020182667 Methods of modulating T lymphocyte costimulation
12/05/2002	US20020182660 Diagnosing alzheimer's disease in humans; obtain sample containing amyloid peptides, incubate with antibodies, presence of preferential peptide indicates alzheimer's disease
12/05/2002	US20020182659 Method to determine TGF-beta
12/05/2002	US20020182639 Synthetic peptides for cartilage resorption assays
12/05/2002	US20020182638 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/05/2002	US20020182621 Methods and compositions using cap43 proteins and nucleic acids to diagnose and treat cancer and other disorders
12/05/2002	US20020182618 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/05/2002	US20020182254 Biodegradable blend of polycaprolactone and crystallization modifier composed of a crystalline fatty acid or crystalline fatty acid ester of polyhydric alcohol for use in the controlled release of biologically active proteins
12/05/2002	US20020182219 Cancer immunotherapy
12/05/2002	US20020182218 Therapeutic anti-melanoma compounds
12/05/2002	US20020182214 Tumor associated internalizing antigens and methods for targeting therapeutic agents
12/05/2002	US20020182213 Method for the treatment of fibrosis
12/05/2002	US20020182212 Compositions and methods for treating hyperimmune response in the eye
12/05/2002	US20020182210 Treatment of central nervous system diseases by antibodies against glatiramer acetate
12/05/2002	US20020182208 Glycosylated antibody
12/05/2002	US20020182207 Contacting said target molecule with a catalyst capable of chemically modifying said target molecule; catalyzing the attachment of the label to the target substance
12/05/2002	US20020182206 Treating an inflammatory disease by administrating a therapeutically effective amount of a PRO301, PRO362 or PRO245 antagonist, or fragment thereof.
12/05/2002	CA2616769A1 Compositions and methods of increasing stress tolerance in plants
12/05/2002	CA2449056A1 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
12/05/2002	CA2449026A1 Use of polyclonal immunoglobulins
12/05/2002	CA2449000A1 Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis
12/05/2002	CA2448956A1 Anti-ngf antibodies for the treatment of various disorders
12/05/2002	CA2448362A1 B7 related protein-2 molecules and uses thereof
12/05/2002	CA2448348A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
12/05/2002	CA2448345A1 Stable liquid formulations of antibodies
12/05/2002	CA2448148A1 Carbohydrate-associated proteins
12/05/2002	CA2448146A1 Secreted proteins
12/05/2002	CA2448116A1 Molecules for disease detection and treatment
12/05/2002	CA2448109A1 Alternative splice forms of proteins as basis for multiple therapeutic modalities
12/05/2002	CA2448104A1 Wnv core protein/capsid interacting protein and uses of the same
12/05/2002	CA2448100A1 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same
12/05/2002	CA2447916A1 Tumor endothelial marker 7.alpha. molecules and uses thereof
12/05/2002	CA2447879A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002	CA2447691A1 Secretion of proteins by encapsulated cells
12/05/2002	CA2447662A1 Transporters and ion channels
12/05/2002	CA2446723A1 Antibodies that immunospecifically bind to trail receptors
12/05/2002	CA2445611A1 P-cadherin as a target for anti-cancer therapy
12/05/2002	CA2443713A1 Proteins associated with cell growth, differentiation, and death
12/04/2002	EP1262562A2 Actinomycetes polynucleotides
12/04/2002	EP1262548A1 Polypeptide inducing apoptosis
12/04/2002	EP1262493A1 Diagnostic assay for latent matrix metalloproteinase no. 9
12/04/2002	EP1262492A1 Antibody to hepatocyte growth factor activator inhibitor-1 and use thereof
12/04/2002	EP1262491A2 Non-anaphylactogenic IgE vaccines
12/04/2002	EP1262486A1 Sodium-independent small neutral amino acid transporters transporting l- and d-amino acids and genes thereof
12/04/2002	EP1262194A1 Remedies and preventives for antiphospholipid antibody syndrome
12/04/2002	EP1262193A1 Use of human anti-CTLA-4 antibodies for treatment of cancer
12/04/2002	EP1262192A2 Compositions and methods for human gastrointestinal health
12/04/2002	EP1262175A2 Use of renin-angiotensin antagonist for reducing post myocardial infarct mobidity and mortality
12/04/2002	EP1261874A1 Specific monoclonal antibody against terbinafine
12/04/2002	EP1261745A2 Nucleic acids, proteins, and antibodies
12/04/2002	EP1261744A2 Estrogen receptor beta variants and methods of detection thereof
12/04/2002	EP1261736A2 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides
12/04/2002	EP1261721A1 Human extracellular signal regulated kinases
12/04/2002	EP1261714A2 Muteins of interleukin-13 (il-13)
12/04/2002	EP1261713A2 Human ion channels
12/04/2002	EP1261712A2 Proteins named fctrx and nucleic acids encoding same
12/04/2002	EP1261709A1 Human abc transporter expressed in liver, atil
12/04/2002	EP1261708A2 Compositions and methods for the therapy and diagnosis of prostate cancer
12/04/2002	EP1261706A2 Egg specific surface proteins
12/04/2002	EP1261704A2 Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
12/04/2002	EP1261703A1 Nucleic acids, proteins, and antibodies
12/04/2002	EP1261700A2 Cis acting regulatory nucleic acid sequences in the parathyroid hormone 3'-untranslated region
12/04/2002	EP1261645A1 Anti-viral conjugate comprising a factor allowing the translocation of a protein across a cell membrane and comprising a single-chain antibody fragment directed against a viral protein
12/04/2002	EP1261644A2 Modulation of the activity of the endothelial cell surface receptor ecrtp/dep-1 in the regulation of angiogenesis
12/04/2002	EP1261643A1 Composition for inhibiting macrophage activity
12/04/2002	EP1261642A1 Antibodies binding a gamma carboxyglutamic acid displaying epitope
12/04/2002	EP1261641A1 Diagnostic method using expression of mn/ca9 protein in agus pap smears
12/04/2002	EP1261639A2 Chondromodulin-i related peptide
12/04/2002	EP1261638A2 Human fgf-23 gene and gene expression products
12/04/2002	EP1261637A1 Nucleic acids, proteins, and antibodies
12/04/2002	EP1261636A2 Human protein kinases and protein kinase-like enzymes
12/04/2002	EP1261635A1 Human polynucleotides, polypeptides, and antibodies
12/04/2002	EP1261634A1 Nucleic acids, proteins, and antibodies
12/04/2002	EP1261633A2 Nucleic acids, proteins, and antibodies
12/04/2002	EP1261631A1 A 52 kDa PROTEIN FROM COAGULASE NEGATIVE STAPHYLOCOCCI AND FRAGMENTS THEREOF
12/04/2002	EP1261627A2 Antibodies against plasma cells
12/04/2002	EP1261618A2 Nucleic acids, proteins, and antibodies

1 ... 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 ... 1494